These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 20551062

  • 1. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.
    Cancer Res; 2010 Jul 01; 70(13):5475-85. PubMed ID: 20551062
    [Abstract] [Full Text] [Related]

  • 2. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T, Yang L, Zhang J.
    Oncol Rep; 2015 Mar 01; 33(3):1215-20. PubMed ID: 25586125
    [Abstract] [Full Text] [Related]

  • 3. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 01; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 4. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
    Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R.
    Cancer Chemother Pharmacol; 2010 Mar 01; 65(4):697-706. PubMed ID: 19636556
    [Abstract] [Full Text] [Related]

  • 5. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN, Andriu A, Smith TA.
    Breast Cancer Res Treat; 2014 Apr 01; 144(2):241-8. PubMed ID: 24522376
    [Abstract] [Full Text] [Related]

  • 6. Sensitization of breast cancer cells to radiation by trastuzumab.
    Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z.
    Mol Cancer Ther; 2003 Nov 01; 2(11):1113-20. PubMed ID: 14617784
    [Abstract] [Full Text] [Related]

  • 7. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.
    Oncogene; 2014 Jun 26; 33(26):3422-31. PubMed ID: 23912457
    [Abstract] [Full Text] [Related]

  • 8. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
    Eddy SF, Kane SE, Sonenshein GE.
    Cancer Res; 2007 Oct 01; 67(19):9018-23. PubMed ID: 17909003
    [Abstract] [Full Text] [Related]

  • 9. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.
    Breast Cancer Res Treat; 2010 Sep 01; 123(2):387-96. PubMed ID: 19946741
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
    Marches R, Uhr JW.
    Int J Cancer; 2004 Nov 10; 112(3):492-501. PubMed ID: 15382077
    [Abstract] [Full Text] [Related]

  • 11. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC.
    Mol Cancer Ther; 2007 Nov 10; 6(11):2843-57. PubMed ID: 18025271
    [Abstract] [Full Text] [Related]

  • 12. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG, Mani S.
    Mol Cancer Ther; 2002 Jul 10; 1(9):695-706. PubMed ID: 12479366
    [Abstract] [Full Text] [Related]

  • 13. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.
    Ann Oncol; 2010 Feb 10; 21(2):255-262. PubMed ID: 19633047
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
    Lu Y, Zi X, Pollak M.
    Int J Cancer; 2004 Jan 20; 108(3):334-41. PubMed ID: 14648698
    [Abstract] [Full Text] [Related]

  • 15. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L.
    Oncogene; 2008 Aug 28; 27(37):5019-32. PubMed ID: 18469855
    [Abstract] [Full Text] [Related]

  • 16. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway.
    Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC.
    Cell Cycle; 2006 Aug 28; 5(15):1654-61. PubMed ID: 16861913
    [Abstract] [Full Text] [Related]

  • 17. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.
    PLoS One; 2010 Feb 02; 5(2):e9024. PubMed ID: 20126311
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS, Arnold SL, O'Regan RM, Nahta R.
    Anticancer Agents Med Chem; 2012 Feb 02; 12(2):151-62. PubMed ID: 22043997
    [Abstract] [Full Text] [Related]

  • 19. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S, Montero JC, Ocaña A, Pandiella A.
    J Natl Cancer Inst; 2010 Sep 22; 102(18):1432-46. PubMed ID: 20811002
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 22; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.